Minimally invasive system for faster,

simpler and cheaper detection of breast cancer metastasis.

More info

Non-invasive system for faster,

simpler and cheaper detection of breast cancer metastasis.

More info


Cancer metastasis is responsible for 90% of cancer related deaths. In breast cancer, metastasis occurs mostly via the lymphatic system. The lymphatic nodes that are closest to a tumour are the most likely route for the cancer cells to first enter the lymphatic system and are referred to as the sentinel lymph nodes (SLN).
Diagnosing the presence of cancerous cells within the SLN is therefore critical to provide optimum treatment plans. The gold standard is currently the Sentinel Lymph Node Biopsy (SLNB). SLNB however comes with several drawbacks.

The HypoSens imaging system is strategically designed to offer a minimally invasive alternative to the SLNB. The device is a prognostic solution for clinicians towards, once validated more accurate and fast diagnosis and personalised treatment options.

Why use HypoSens system


The photonics system uses tumour targeted nano-confined sensors for intracellular temperature and oxygen sensing.

Minimally invasive

HypoSens does not require surgery to test the lymph node status.


HypoSens will produce results in real-time.


The nano-confined sensor particles will be able to monitor both temperature and dissolved oxygen. Coupling the nano-sensors with target antigens ensures the proper identification of the targeted tumour cells.


The prognosis system does not release any ionising radiation.


The device will incorporate a “plug and play” architecture which will render it easy to operate.


Due to the compact nature of the imaging system, the development of HypoSens will result in a decrease in the diagnostic costs associated with metastatic breast cancer.

Private Zone
Access to intranet